HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: iovs.08-3239v1 50/9/4244    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Bull, N. D. Articles by Martin, K. R. Search for Related Content PubMed PubMed Citation Articles by Bull, N. D. Articles by Martin, K. R.

Transplanted Oligodendrocyte Precursor Cells Reduce Neurodegeneration in a Model of Glaucoma

¹From the Centre for Brain Repair and NIHR (National Institute for Health Research) Biomedical Research Centre, and the ³Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom; and the ²Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, California.

PURPOSE. Glaucoma is a common neurodegenerative disease for which current therapies are often insufficient; thus, new neuroprotective strategies are an important goal. Stem cells are attracting increasing attention as mediators of neuroprotection, often conferred via the trophic support of injured neurons. The purpose of our investigation was to determine whether oligodendrocyte precursor cells (OPCs), a type of neural stem cell, can protect retinal ganglion cells (RGCs) from glaucomatous damage in vivo.

METHODS. Intraocular pressure was chronically increased by trabecular laser treatment delivered unilaterally to adult rat eyes. OPCs were isolated in vitro and then transplanted intravitreally either before, or concurrent with, injury induction. Survival, migration, differentiation, and integration of grafted cells were assessed by immunohistochemistry. RGC survival was assessed by optic nerve axon quantification.

RESULTS. Transplanted OPCs were found to survive within the eye for at least 12 weeks and to localize close to the RGCs. Moreover, OPCs significantly enhanced the survival of RGCs in the glaucomatous eye, but only when concomitantly activated by inflammation. Axonal loss relative to the untreated fellow eye was 28.34% ± 11.51% in eyes that received activated OPCs, compared with 60.34% ± 8.28% in control eyes (mean ± SEM; P = 0.05). Amelioration of RGC death was not attributable to inflammation but relied on an interaction between inflammatory cells and OPCs. Engrafted cells also displayed multipotentiality in vivo.

CONCLUSIONS. The impressive neuroprotection conferred by OPCs in this model suggests stem cell–based therapies should be explored further as a potential treatment for glaucoma.

This article has been cited by other articles:

				J. J. Stanke and A. J. Fischer Embryonic Retinal Cells and Support to Mature Retinal Neurons Invest. Ophthalmol. Vis. Sci., April 1, 2010; 51(4): 2208 - 2218. [Abstract] [Full Text] [PDF]

				T. V. Johnson, N. D. Bull, D. P. Hunt, N. Marina, S. I. Tomarev, and K. R. Martin Neuroprotective Effects of Intravitreal Mesenchymal Stem Cell Transplantation in Experimental Glaucoma Invest. Ophthalmol. Vis. Sci., April 1, 2010; 51(4): 2051 - 2059. [Abstract] [Full Text] [PDF]